News Releases

These are news releases that are related to our company, pipeline and investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Sep 1, 2022

Summary Toggle aTyr Pharma to Present Poster at the European Respiratory Society (ERS) International Congress 2022

SAN DIEGO , Sept. 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present a poster on Monday, September
Aug 15, 2022

Summary Toggle aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update

First sites initiated in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis. FDA granted Fast Track designation for efzofitimod for the treatment of pulmonary sarcoidosis. Ended the second quarter 2022 with $89.3 million in cash, restricted cash, cash equivalents and investments.
Aug 12, 2022

Summary Toggle aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO , Aug. 12, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary tRNA synthetase biology platform, today announced that the Compensation Committee of aTyr’s Board of
Aug 11, 2022

Summary Toggle aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis

Company is investigating efzofitimod in global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis patients SAN DIEGO , Aug. 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a clinical stage biotherapeutics company engaged in the discovery and development
Aug 4, 2022

Summary Toggle aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2022 Financial Results

Management to host conference call and webcast on August 15th at 5:00 pm EDT / 2:00 pm PDT SAN DIEGO , Aug. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA
Jun 14, 2022

Summary Toggle aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment

Poster to be presented at the Keystone Symposia on Tissue Fibrosis and Repair. Second tRNA synthetase receptor identified from company’s platform. Findings suggest AARS fragment may have therapeutic potential in fibrosis, inflammation and cancer. SAN DIEGO , June 14, 2022 (GLOBE NEWSWIRE) -- aTyr
Jun 13, 2022

Summary Toggle aTyr Pharma to Present Findings from its tRNA Synthetase Platform at the International 28th tRNA Conference

Conference hosted by The Ohio State University’s Center for RNA Biology to showcase latest advancements in tRNA biology SAN DIEGO, June 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from
Jun 1, 2022

Summary Toggle aTyr Pharma to Present at the 2022 Jefferies Healthcare Conference

SAN DIEGO , June 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines from its proprietary tRNA synthetase biology platform, today announced that Sanjay S.
May 17, 2022

Summary Toggle aTyr Pharma Presents Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference

Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate dose-dependent improvements in key physiologic and quality of life measures in context of a steroid taper. Efzofitimod treatment reduces pro-inflammatory serum biomarkers in pulmonary sarcoidosis patients.
May 16, 2022

Summary Toggle aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis

Global pivotal EFZO-FIT™ study expected to begin in the third quarter of 2022 Primary endpoint will evaluate steroid sparing effect of efzofitimod compared to placebo SAN DIEGO , May 16, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery